Stock AnalizHealthequity, Inc. HQY
Business Services · IPO 2014 · data as of November 13, 2026
Healthequity, Inc. (HQY) is a consumer discretionary company listed in the US with a market value of about $8.6B. In the twelve months to July 31, 2026 it had revenue of $1.4B and net income of $236M, a net margin of 17.4%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 37.4, a price to free cash flow of 17.5, 5-year revenue growth of 12% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 50% below the current price.
Score: 2.8 / 5
Checks passed
- P/FCF below 20
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Pays a dividend
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.2B | $1000M | $862M | $757M | $734M | $532M | $287M | $230M | $178M |
| Net income | $236M | $215M | $97M | $56M | -$26M | -$44M | $9M | $40M | $74M | $47M | $26M |
| Free cash flow | $488M | $455M | $338M | $241M | $147M | $132M | $169M | $98M | $110M | $76M | $42M |
| EPS (diluted) | $2.77 | $2.46 | $1.09 | $0.64 | $-0.31 | $-0.53 | $0.12 | $0.58 | $1.17 | $0.77 | $0.44 |
| Net margin | 17.4% | 16.4% | 8.1% | 5.6% | -3.0% | -5.9% | 1.2% | 7.5% | 25.7% | 20.6% | 14.8% |
| ROIC | — | 8.1% | 4.2% | 2.9% | 0.2% | -0.6% | 1.1% | 3.0% | 15.9% | 14.3% | 10.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $120.67, 17% above the current price; targets range from $108.00 to $142.00; the consensus rating is “none”; expected EPS is $4.72 for the fiscal year ending January 31, 2027.
Frequently asked questions
What is Healthequity’s P/E ratio?
About 37.4, based on the last twelve months of diluted earnings per share (forward P/E about 20.6).
Is Healthequity stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 50% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Healthequity pay a dividend?
Not currently.
Is Healthequity a good stock to buy?
We do not give buy or sell advice. Healthequity scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.